#ALZsky

A&D is excited to support this collaborative research! #AlzSky

Schaeffer Research Featured in Special Journal Issue on Alzheimer’s Care and Caregiving - April 7, 2026 - USC Schaeffer Topics include government support for informal care partners, clinical trial research participation and the societal cost of cognitive impairment. - April 7, 2026

Read highlights from USC Schaeffer scientists @zisspolicyusc.bsky.social and Andrea Gilmore-Bykovskyi in the A&D Special Collection: Advancing Dementia Care and Caregiving Science in Alzheimer’s Disease and Related Dementias (ADRD) #AlzSky

schaeffer.usc.edu/research/sch...

Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer’s disease pathogenesis - Nature Aging Young, cognitively normal APOE4 mice display hippocampal network hyperactivity that predicts later memory decline. This phenotype is driven by neuronal APOE4 expression, which causes hyperexcitability of hippocampal neurons and can be reversed by targeting Nell2.

A study in Nature Aging shows that the strongest Alzheimer’s Disease risk gene, APOE4, can make certain brain cells in young mice hyperactive, which can predict later memory decline. The study also implicates Nell2 protein as a contributor to APOE4-driven dysfunction. #Alzsky 🧬🧪

Insights from #AAIC25 Satellite Symposium in Peru now in A&D!

Experts convened by the @alzassociation.bsky.social, Atlantic Fellows for Equity in Brain Health, & GBHI Fellows share emerging approaches to advance dementia research, prevention & care across Latin America #AlzSky

bit.ly/4cimeHN

Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer’s disease pathogenesis - Nature Aging Young, cognitively normal APOE4 mice display hippocampal network hyperactivity that predicts later memory decline. This phenotype is driven by neuronal APOE4 expression, which causes hyperexcitability of hippocampal neurons and can be reversed by targeting Nell2.

A study in Nature Aging shows that the strongest Alzheimer’s Disease risk gene, APOE4, can make certain brain cells in young mice hyperactive, which can predict later memory decline. The study also implicates Nell2 protein as a contributor to APOE4-driven dysfunction. #Alzsky 🧬🧪

Explore the latest issue of #TRCI for key takeaways from the spring 2025 @alzassociation.bsky.social Research Roundtable on advances in biomarkers, prevention & treatment approaches before cognitive symptoms. #AlzSky

Learn More: alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

This is figure 2, which shows speech and language changes in healthy and pathological ageing.

A Review in Nature Reviews Psychology outlines key age-related changes in speech and language abilities and how these typical changes differ from changes observed in Alzheimer’s dementia. go.nature.com/4tzus5j #alzsky 🧪

Incredibly excited that the lab's first papers is now published! We use AI to simultaneously predict multiple neurodegenerative disease diagnoses from plasma proteomics. Congrats @anlijuncn.bsky.social !

#MedSky #neuroskyence #neurosky #alzsky #compneuro #ai #datascience #bioinformatics #neurology

What are the effects of progressive resistance training (PRT) on cognitive function in adults with subcortical vascular cognitive impairment (SVCI)?

New in A&D! PRT may have a small beneficial effect on cognitive function in SVCI #AlzSky

alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms - Molecular Neurodegeneration Alzheimer’s Disease (AD) is a progressive and ultimately fatal neurodegenerative disorder, representing the most common form of dementia and affectin

A Review in Molecular Neurodegeneration identifies the key pathways in Alzheimer’s disease, discusses emerging biomarkers, tools and strategies for discovery and analysis, and emphasizes on the advances related to the emerging precision medicine for AD.

#MedSky #AlzSky

Synbiotics in Alzheimer’s disease: mechanisms, clinical evidence, and therapeutic prospects - Journal of Translational Medicine Background Growing evidence implicates gut microbiota (GM) dysbiosis in Alzheimer’s disease (AD) pathogenesis via the gut-brain axis. Dysbiosis contributes to neuroinflammation, amyloid-β deposition, tau hyperphosphorylation, blood-brain barrier disruption, and cognitive decline. Synbiotics (combinations of probiotics and prebiotics) offer a promising strategy to modulate GM, potentially ameliorating these AD hallmarks through multiple mechanisms including enhanced production of neuroprotective short-chain fatty acids (SCFAs), reduced inflammation, improved gut barrier integrity, and immunomodulation. Objective This review critically evaluates the current evidence on the therapeutic potential of synbiotics for AD. It aims to synthesize findings from preclinical and clinical studies regarding the efficacy of synbiotics in improving cognitive function and AD pathology, elucidate the underlying biological mechanisms including GM modulation, SCFA production, immune regulation, and gut-brain signaling, and identify key challenges and future research directions for translating GM-targeted interventions into effective AD therapies. Conclusion Synbiotics demonstrate significant potential, particularly in early AD, by improving cognitive domains, reducing neuroinflammation and AD biomarkers, and modulating beneficial microbial metabolites. However, challenges include confounding factors, unresolved questions about causality, inconsistent results in advanced disease, and insufficient large-scale human trials. Future success hinges on rigorous longitudinal randomized controlled trials integrating multi-omics approaches, advanced in vitro models, and personalized strategies considering baseline microbiota and host genetics. While not a standalone cure, synbiotics represent a valuable component within multi-target therapeutic approaches aimed at modulating the gut-brain axis to slow AD progression.

A Review in the Journal of Translational Medicine shows that synbiotics (combinations of probiotics and prebiotics) have significant potential in early Alzheimer’s, by improving cognitive domains, reducing neuroinflammation, and modulating beneficial microbial metabolites.

#MedSky #alzsky

Research progress of exosomes used in the Alzheimer's disease treatment - Discover Nano Abstract Alzheimer's disease (AD) is a common form of dementia characterized by memory loss, cognitive and linguistic abilities declining and self-care capabilities diminishment. With the aging population globally, AD poses a significant threat to public health. Current treatments for AD aim to alleviate symptoms and slow down disease progression, but due to the limited understanding of underlying disease mechanisms, AD is still impossible to be cured yet. In recent years, there has been an exponential growth in exosome-related research because of their excellent biocompatibility ability, loading capacity and cellular internalization, making exosome to be one of the hotspots and a promising strategy in AD therapy research. This comprehensive review systematically explores the potential roles of various exosome-based nanotherapeutic strategy in AD treatment, with a particular focus on their specific biological mechanisms of action. Firstly, we elaborated on the pathological mechanisms of AD formation as well as the mechanisms related to the formation, secretion and function of exosome. Additionally, we highlighted the research progress in the development of exosome-based nanotherapeutic strategies for AD treatment and their corresponding biological mechanisms. Furthermore, we delved into the challenges and opportunities these strategies facing in clinical application. Looking forward to future research directions and trends, our review aims to provide a more comprehensive understanding and guidance with the application of exosome in AD treatment. Exosome-based nanotherapeutic strategies, as a new therapeutic approach, have opened up new possibilities for the treatment of AD and brought new light to patients. Graphical abstract Schematic diagram of exosome-based nanotherapy strategies for the treatment of AD. It can be roughly classified as: exosomes-based methods treating AD and bioengineered exosomes for the treatment of AD.

A Review published in Discover Nano explores the potential roles of various exosome-based nanotherapeutic strategies in Alzheimer’s disease treatment, with a particular focus on their mechanisms of action.

#MedSky #alzsky

How do blood-based biomarkers associate depressive symptoms and Alzheimer’s disease risk? #AlzSky

Key Details:
🩸11,947 non-demented adults ≥ 70 years
🩸Higher glial fibrillary acidic protein (GFAP) was associated with higher depressive symptoms

alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Flyer for the Computational Techniques for Effective Translational Research in AD workshop. See event webpage for more information.

Strengthen your computational skills with in‑depth bioinformatics training to power multi‑scale data in your translational #AlzheimersDisease research at @jacksonlab.bsky.social’s workshop: www.jax.org/education-an...

#NeuroSkyence #AlzSky #CompNeuro

More details! 👇

New research in A&D!

Engaging Chinese and Korean American communities in dementia research: A journey of inclusivity and partnership #AlzSky

Key Findings:
🟣Culturally adapted recruitment strategies
🟣Community partnerships
🟣and More!

Article: alz-journals.onlinelibrary.wiley.com/doi/full/10....

A&D Call For Papers!

Spotlight on Alzheimer’s disease and related dementias research in South Asia

Enhance understanding of the diverse characteristics, ethnic variability, and complexity of ADRD! #AlzSky

⏰: June 30, 2026

alz-journals.onlinelibrary.wiley.com/hub/journal/...

New voices in biomarker research for neurodegenerative diseases Detecting and monitoring the pathophysiology underlying neurodegenerative diseases remains a major challenge in ensuring treatment of the right individual ...

The first papers in the “New voices in biomarker research for neurodegenerative diseases” Collection in Alzheimer's Research & Therapy are now published. Early career researchers can still submit their work until 21 August 2026.

#MedSky #AlzSky

Check out this amazing special issue! It is more than critical to highlight dementia research worldwide!
#AlzSky

New Special Issue Out in A&D!

Global Spotlight Series: Dementia Research in Africa

This collection showcases Africa's research in dementia to ensure visibility to policymakers, health systems, and the community #AlzSky 🧵(1/2)

Published Issue: alz-journals.onlinelibrary.wiley.com/doi/toc/10.1...

New research in A&D focuses on neuroinflammation, long-COVID, and Alzheimer's disease! #AlzSky

Results: Choroid plexus differences in long COVID are associated with AD-related cognitive decline and increased plasma biomarkers

Full article: alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

#MedSky #neuroskyence #neurosky #alzsky #compneuro #datascience #neurology

Serum Klotho Levels, Brain Structure, and Cognitive Performance This cross-sectional study investigates if circulating serum klotho levels modify the negative association between age-related brain atrophy and cognitive decline in a cognitively unimpaired, older ad...

La protéine klotho circulante pourrait elle être un marqueur de longévité cérébrale ?

@fredericblanc.bsky.social #alzsky

Plasma p-tau217 Cutoffs, Kidney Function, BMI, and Anemia This cohort study compares the performance of 3 plasma p-tau217 classification strategies for detecting amyloid-β positivity to consider which offers better optimize diagnostic accuracy and cost effic...

Comment mieux interpréter la pTAU217 au regard de l’insuffisance rénale chronique, de l’IMC et de la présence d’une anémie
#alzsky

Don't miss out on this opportunity to highlight your dementia research focused in South Asia! #AlzSky

Biochemical signatures of skin α-synuclein in synucleinopathies revealed by RT-QuIC assay end-product analysis Synucleinopathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), share pathological accumulation of misfolded α-synuclein (αSyn) in the brain and overlapping clinical features, complicating ...

La RT-QuIC synucleine est positive sur des biopsies cutanées, et les auteurs suggèrent des différences au niveau des fibres selon Maladie à corps de Lewy, maladie de Parkinson ou atrophie multi systématisée

pmc.ncbi.nlm.nih.gov/articles/PMC...

#alzsky @fredericblanc.bsky.social

How are dementia or Mild Cognitive Impairment associated with life expectancy?

Check out this recent study from the Norwegian Registry of Persons Assessed for Cognitive Symptoms (NorCog) published in #DADM to learn more!

alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

#AlzSky

Client Challenge

On sous estime probablement le lien entre maladies neuro évolutives, EEG épilepsies notamment focales : de plus en plus d’arguments dans la MA comme la MCL comme la sclérose hippocampique
#alzsky

doi.org/10.1186/s131...

Alpha-synuclein seeding activity in postmortem tissues from patients with diffuse and isolated Lewy bodies We have evaluated the diagnostic potential of the seeding amplification assay (SAA) in detecting α-synuclein seeding activity in postmortem brain and cerebrospinal fluid (CSF) samples from patients with primary and co-pathology α-synucleinopathies. ...

Toujours d’excellents résultats pour la détection de la synucleine par les SAA, avec ici des formes amygdaliennes @fredericblanc.bsky.social et l’utilisation du SDS semble augmenter les performances

#alzsky

pmc.ncbi.nlm.nih.gov/articles/PMC...

Learn about the relationship between the Quick Dementia Rating System (QDRS) and AD biomarker plasma pTau217 for predicting cognitive decline. Read the full study recently published in #DADM!

alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

#AlzSky

New research in #BSEA examines barriers to to care for Fronto Temporal Dementia (FTD). This article explores whether residing in Medicaid-expanded states is associated with diagnostic experiences among individuals with FTD.

alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

#AlzSky